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Transcatheter aortic valve implantation (TAVI) is the therapy of choice 
for patients with symptomatic severe aortic stenosis who are unsuitable 
for surgical aortic valve replacement and for elderly patients with high 
operative risk.1,2 It is also considered to be a more than valid and 
reasonable alternative to surgical aortic valve replacement for patients 
with moderate to high surgical risk.3,4 Of note, two recently published 
trials assessing TAVI in low-risk patients have shown that TAVI is at least 
non-inferior and is likely to be superior to surgery in major outcomes in 
this scenario.5,6 Overall, these findings suggest that indications for TAVI 
will be expanded and the number of patients treated with this technique 
will continue to grow exponentially in the near future.
Improvements in patient assessment, new generation devices and 
greater operators’ experience have certainly contributed to an increase 
in the efficacy and safety of the procedure over the years. Despite this, 
thromboembolic and bleeding complications after TAVI remain 
prevalent and affect morbidity and mortality. Indeed, TAVI interventions 
are associated with the occurrence of thrombotic and haemorrhagic 
events, which can occur periprocedurally or during the short- or long-
term follow up after the index procedure.7,8 Given the observed 
important rise in the number of interventions, it is of utmost relevance 
to determine the optimal antithrombotic strategy after TAVI. In this 
scenario, an accurate assessment of the balance between thrombotic 
and bleeding risk, which can be augmented if an unnecessarily potent 
antithrombotic regimen is chosen, is critical. The aim of this article is to 
provide a brief and comprehensive overview of the current status of 
knowledge on antithrombotic treatment strategies following TAVI 
procedures, focusing on guidelines recommendations and the available 
evidence to support them, and of currently on-going trials that are 
evaluating different antithrombotic regimens in this scenario.
Adverse Events After Transcatheter 
Aortic Valve Implantation
Both thromboembolic and bleeding events after TAVI are major 
concerns due to their prognostic impact. These complications may be 
associated with procedural issues, but also with underlying risk factors 
in the long term, taking into consideration that these procedures are 
often performed in elderly and frail patients with several comorbidities.
Early thromboembolic events can be considered mainly procedural, 
and due to device positioning and implantation. Periprocedural 
complications include cerebrovascular events (CVEs), systemic 
embolisation and MI. Of note, several factors and phenomena occurring 
during TAVI and in the early postprocedural period contribute to create 
a prothrombotic environment. These include: native leaflets are not 
removed and may be mechanically damaged during TAVI, which may 
lead to embolisation of small valve fragments and to the exposure in 
the bloodstream of molecules that help increasing thrombogenicity 
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and inflammation (unlike normal valves, stenotic valve leaflets are rich 
in tissue factor and thrombin); changes in the flow patterns that may 
predispose to thrombus formation; and other mechanisms occurring 
during positioning and implantation (aortic wall injury, air embolism, 
rapid pacing or haemodynamic instability that may lead to cerebral 
hypoperfusion, etc.).7–10 
CVEs are undoubtedly among the most feared complications of TAVI, 
since they have a considerable impact on morbidity and mortality.11–13 
The greatest risk of suffering a clinically apparent stroke is within 24–48 
hours after TAVI, but remains high for up to 2–3 months. The rates of 
CVEs (including transient ischaemic attacks and strokes) are highly 
variable among published studies, ranging from approximately 2–6% at 
30 days, and reaching 7–9% at 1 year of follow-up.11,13 Acute events can 
be clearly attributed to procedural issues (i.e. device manipulation, 
repeated positioning or post-valve deployment balloon dilatation), 
whereas the main underlying cause of subacute (1–30 days) and late 
(>30 days) events is the presence of AF. The prevalence of AF among 
TAVI candidates (usually elderly patients) ranges approximately 20–
50%, and is the major predictor of late CVEs in this population.14,15 
In addition, 10–30% of patients develop new-onset AF after TAVI, which 
is less frequent with the transfemoral approach. Remarkably, new-
onset AF is often undiagnosed, and it represents an important predictor 
of subacute CVEs. Overall, TAVI patients with AF have a high baseline 
cardioembolic risk, and both pre-existing and new-onset AF appear to 
be associated not only with CVEs, but also with mortality, although 
controversial results can be found in the scientific literature.14–17 
Therefore, efforts should be made to properly diagnose and treat AF, 
which may frequently require chronic anticoagulation therapy, in this 
subset of patients.
The incidence of MI after TAVI is relatively low (1–2%) and mostly 
restricted to the periprocedural period, thus, it may reflect myocardial 
injury during the procedure. A higher degree of myocardial injury has 
been associated with increased mortality in some studies, but other 
investigations failed to observe a prognostic impact in TAVI patients.18–21 
Nevertheless, it is relevant to identify coronary artery disease in TAVI 
candidates, since both conditions frequently coexist (30–70%) and the 
severity of coronary artery disease might impact prognosis after TAVI.22–24 
The decision about revascularisation, its completeness and timing 
(staged or concomitant procedures) should be made on a case-by-case 
basis for patients undergoing TAVI. Regardless, a period of dual 
antiplatelet therapy (DAPT) after coronary revascularisation is mandatory, 
which has also evident implications in the decision-making process of 
selecting the antithrombotic treatment regimen after TAVI.25,26
The spectrum of bioprosthetic leaflet thrombosis comprises subclinical 
imaging findings, such as early reduced leaflet motion and hypoattenuated 
leaflet thickening, to clinically apparent valve thrombosis with elevated 
gradients and clinical manifestations (i.e. heart failure, valve dysfunction 
and stroke or systemic embolisms).27,28 Its pathogenesis is not completely 
known, although several mechanisms are involved, including surface, 
haemostatic and haemodynamic factors.29 The presence of 
hypoattenuated leaflet thickening and reduced leaflet motion is not 
infrequent after TAVI (up to 10–15% of cases). 
A retrospective observational study reported that reduced leaflet motion 
could be associated with a higher risk of stroke.30 However, it remains 
uncertain whether these imaging abnormalities are clinically meaningful 
or just represent a subclinical finding. Fortunately, clinical valve 
thrombosis is an infrequent phenomenon with an estimated incidence of 
0.03–0.07% per year,7 although a single-centre study reported an overall 
incidence of 2.8%, with a median time of diagnosis of approximately 6 
months after the procedure.30 Of note, predictors of clinical valve 
thrombosis are the use of a balloon-expandable device (compared with 
self-expanding or mechanically expanded devices), a valve-in-valve 
procedure and treatment with antiplatelet agents alone.30 Interestingly, 
the use of oral anticoagulation (OAC) has consistently shown to be 
effective in reducing valve thickening and transvalvular gradients in the 
majority of cases of subclinical or clinical valve thrombosis, although the 
risk–benefit balance remains to be determined.28,30 
Bleeding events also play a major role in short- and long-term prognosis 
after TAVI, and its severity can be categorised, for the sake of 
standardisation, according to the Valve Academic Research Consortium 
criteria.31 Indeed, early and late haemorrhagic events have a negative 
impact on cardiovascular mortality.32,33 Early (<30 days) major bleeding 
complications after TAVI are frequent (10–15%), and represent a strong 
independent predictor of early mortality.32 They are mostly due to vascular 
or access-site complications, with pericardial bleeding being less common. 
The improvement in operators’ experience and in new generation 
devices (reduction in sheaths size) is leading to a reduction in the 
events related with the procedural technique. Remarkably, late (>30 
days) bleeding events are associated with an important increase in 
mortality risk of more than threefold.33 Regarding late outcomes, non-
access-site bleeding has a greater impact on prognosis, with 
gastrointestinal haemorrhages being the most frequent location. 
Importantly, late bleeding complications may be attributed to the 
baseline risk of patients undergoing TAVI, but antithrombotic regimens 
also play a role in this vulnerable population.34
Antithrombotic Therapy
There is clearly insufficient evidence nowadays regarding optimal 
adjunct antithrombotic therapy after TAVI, which is reflected in the 
large heterogeneity of drug regimens that are used in clinical practice.35 
In fact, two different hypotheses – the antiplatelet and the antithrombin 
hypotheses – have been postulated to support the use of antiplatelet 
and anticoagulant agents, respectively. Unfortunately, it remains 
unclear whether thromboembolic complications after TAVI are mainly 
due to platelet- or thrombin-mediated clot formation. An accurate 
evaluation of the fine balance between a potential prevention of 
thromboembolic complications without unnecessarily increasing the 
risk of bleeding is crucial to determine the optimal antithrombotic 
therapy in this high-risk population (Figure 1). In this section, we 
summarise current guideline recommendations, most of them 
empirically based, and available evidence regarding the efficacy and 
safety of antiplatelet and anticoagulant agents after TAVI.
Guidelines Recommendations
The recommendations of the European Society of Cardiology and 
American College of Cardiology/American Heart Association regarding 
antithrombotic therapy after TAVI are not uniform.1,2 This is far from 
surprising, as they are mostly based on relatively small non-randomised 
studies and expert consensus. Current guidelines recommendations on 
postprocedural antithrombotic strategies are summarised in Table 1.
European guidelines advocate the use of DAPT with aspirin and 
clopidogrel for the first 3–6 months, followed by lifelong single 
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antiplatelet therapy (SAPT) as the default strategy for patients without 
any other indication for OAC, whereas SAPT may be considered for 
patients with high bleeding risk.1 US guidelines suggest DAPT with 
clopidogrel for the first 6 months in addition to lifelong aspirin, whereas 
OAC with a vitamin K antagonist (VKA) is proposed for at least 3 months 
after TAVI for patients at low risk of bleeding to diminish the risk of 
valve thrombosis.2 Both guidelines agree in recommending lifelong 
OAC for patients with other indications for OAC (the most frequent 
being AF), although no clear statement is provided with regards to the 
need for concomitant antiplatelet therapy in these patients.1,2
Antiplatelet Therapy: Available Evidence
The most widely adopted postprocedural antithrombotic regimen for 
TAVI patients, in the absence of an indication for OAC, is DAPT with 
aspirin (indefinitely) and clopidogrel (3–6 months). This strategy is 
empirical and based, first and foremost, on current recommendations 
for patients undergoing percutaneous coronary interventions.25 Further, 
anatomopathological analyses have suggested that neointimal tissue 
invasion and full endothelialisation of the valve stent frame occur 
approximately 3 months after the procedure, with a decrease in 
thromboembolic events thereafter, which might support this 
antithrombotic strategy.36 Recent evidence, however, has questioned 
the usefulness and safety of DAPT over SAPT with aspirin.
Three small randomised trials have compared DAPT (3 or 6 months) 
with aspirin monotherapy after TAVI (Figure 2).37–39 None of them found 
a significant benefit of DAPT in terms of the prevention of 
thromboembolic events, although the studies were clearly not 
powered to detect differences in ischaemic outcomes due to their 
small sample size. 
The Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic 
Valve Implantation (ARTE) trial was the largest of these studies. ARTE 
compared 3 months of DAPT with SAPT plus aspirin in 222 patients with 
no indication for OAC after implantation of a balloon-expandable 
device, although it was stopped prematurely due to funding issues and 
slow recruitment.39 The net primary endpoint (death, MI, stroke or 
transient ischaemic attack, or major or life-threatening bleeding) 
numerically tended to occur more frequently in the DAPT group (15.3% 
versus 7.2%; p=0.065) at 3 months after the procedure. Of note, no 
statistically significant differences were observed in individual 
ischaemic endpoints or mortality, whereas DAPT was associated with a 
greater rate of major or life-threatening bleeding events compared with 
SAPT (10.8% versus 3.6%; p=0.038).39 
This was corroborated in a patient-level meta-analysis of these three 
randomised trials (n=421), in which DAPT was associated with a higher 
risk of major or life-threatening bleeding events compared with aspirin 
monotherapy at 30 days of follow up (11.4% versus 5.2%; OR 2.24; 95% 
CI [1.12–4.46]; p=0.022) without showing any beneficial effect on 
ischaemic events.40
A recently published mechanistic investigation showed a better 
pharmacodynamic efficacy of ticagrelor compared with clopidogrel 
(both in association with aspirin) in TAVI patients with suboptimal 
response to clopidogrel, as measured with the VerifyNow PRUTest 
(Werfen). The study was not powered to evaluate differences in clinical 
endpoints, and the high level of platelet inhibition achieved with 
ticagrelor should actually suggest caution before prescribing a potent 
antiplatelet agent in this elderly population with a high risk of bleeding. 
Figure 1: Potential Complications and Putative 
Benefits and Limitations of Antithrombotic Strategies 
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Antithrombotic therapy after TAVI
ACS = acute coronary syndrome; APT = antiplatelet therapy; CVE = cerebrovascular event; 
DAPT = dual antiplatelet therapy (aspirin + clopidogrel); DOAC = direct oral anticoagulant; 
OAC = oral anticoagulation; PCI = percutaneous coronary intervention; SAPT = single 
antiplatelet therapy; TAVI = transcatheter aortic valve implantation; VKA = vitamin K 
antagonist.
Table 1. Summary of Current Guidelines 
Recommendations for Antithrombotic Therapy 
After Transcatheter Aortic Valve Implantation
Guideline Recommendations





Dual antiplatelet therapy should be 
considered for the first 3–6 months after 
TAVI, followed by lifelong single 
antiplatelet therapy in patients who do 
not need oral anticoagulation for other 
reasons
IIa, C
Single antiplatelet therapy may be 






Clopidogrel 75 mg daily may be 
reasonable for the first 6 months after 
TAVR in addition to life-long aspirin 75 mg 
to 100 mg daily
IIb, B-NR
Anticoagulation with a VKA to achieve an 
INR of 2.5 may be reasonable for at least 3 
months after TAVR in patients at low risk 
of bleeding
IIb, C
ACC = American College of Cardiology; AHA: American Heart Association; EACTS = European 
Association for Cardio-Thoracic Surgery; ESC = European Society of Cardiology; INR = 
international normalised ratio; TAVI = transcatheter aortic valve implantation; TAVR = 
transcatheter aortic valve replacement.
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Nevertheless, an interesting reflection can be drawn from this trial, as a 
very high percentage of suboptimal responders to clopidogrel (>70%) 
was observed and, thus, it questions again the usefulness of the 
addition of clopidogrel to aspirin in this setting.41
Overall, cumulative data from observational and small randomised 
investigations considered together do not support current common 
practice of DAPT after TAVI, as it has not been proven superior in 
reducing thromboembolic events compared with SAPT with aspirin, 
which could be a safer and similarly effective option.42 Some on-going 
trials that are mentioned below are presently testing this hypothesis 
and will provide important insights on the subject. 
Anticoagulant Therapy: Available Evidence
The above-mentioned effectiveness of OAC in preventing and 
treating subclinical and clinical leaflet thrombosis that has been 
reported in observational studies has provided the rationale for 
suggesting an OAC-based strategy after TAVI, as recommended in 
the US guidelines.2,28,30 However, the evidence supporting this 
recommendation is weak and several doubts may arise, such as the 
duration of OAC that should be prescribed, the actual prognostic 
relevance of subclinical leaflet thrombosis or, more importantly, the 
impact on haemorrhagic events.
Interestingly, in a recent report of the large nationwide FRANCE-TAVI 
registry, OAC at discharge (administered to >70% of cases due to AF) 
was independently associated with a lower risk of valve dysfunction 
and, conversely, with a higher risk of all-cause mortality.43 Indeed, the 
uncertainty of the trade-off between the potential benefit of preventing 
an infrequent entity, such as clinical valve thrombosis, and the potential 
harm of prolonged OAC in patients without AF precludes the use of 
long-term OAC as a default strategy for patients undergoing TAVI.
The management of antithrombotic therapy after TAVI for patients with 
other indications for long-term OAC, with AF being the most frequent 
aetiology, is particularly challenging. As commented previously, the 
presence of AF is very common in patients undergoing TAVI, and is 
associated with an increased risk of cerebrovascular events and 
mortality.14,17 Of note, the addition of antiplatelet therapy to OAC does 
not appear to reduce the incidence of thromboembolic events and 
actually increases the risk of major or life-threatening bleeding.44,45 
Hence, if no other reason for associating antiplatelet agents is present 
(e.g. recent percutaneous coronary intervention), available evidence 
suggests that OAC alone without concomitant antiplatelet therapy may 
be the preferred antithrombotic treatment for TAVI patients with AF.
The use of direct oral anticoagulants (DOACs) appears particularly 
attractive due to their favourable safety profile when compared with 
VKA, particularly for patients at high risk of bleeding or if combination 
with antiplatelet drugs is required.46,47 However, the evidence regarding 
the usefulness of DOACs after TAVI is extremely scarce to date, and is 
mostly based on small subgroup analyses of observational studies. 
According to available data, DOACs may have a similar efficacy as VKA 
in preventing thromboembolic events after TAVI, and also for treatment 
of subclinical leaflet thrombosis.28,48 
A small study even suggested that apixaban might confer a benefit 
(composite endpoint at 30 days of all-cause mortality, all stroke, life-
threatening bleeding, acute kidney injury, coronary obstruction, major 
vascular complications and valve dysfunction requiring re-intervention) 
compared with VKA for patients with AF after transfemoral TAVI.49 
Conversely, a recently published multicentre registry evaluating the 
impact of the type of anticoagulant agent for TAVI patients (n=962) in 
need of OAC therapy showed a higher risk of ischaemic events 
(composite endpoint of all-cause mortality, MI and any cerebrovascular 
event) with the use of DOACs compared with VKA at 1 year of follow up 
without noticing differences in bleeding risk.50 Hence, further 
investigations are warranted to determine the true usefulness of 
DOACs in this scenario and, in fact, several on-going studies are 
evaluating the efficacy and safety of DOACs for TAVI patients with and 
without other indications for OAC.
On-going Studies
Current recommendations of practice guidelines regarding 
antithrombotic therapy after TAVI, as previously mentioned, are not 
fully evidence based. However, this is a very active field of research 
Figure 2: Outcomes of Randomised Clinical Trials Comparing Dual Versus Single Antiplatelet 
Therapy with Aspirin After Transcatheter Aortic Valve Implantation




























A: Ischaemic events (all-cause death, stroke or transient ischaemic attack, or MI) outcomes at 30 days. B: Major or life-threatening bleeding at 30 days.37–39 DAPT = dual antiplatelet therapy 
(aspirin and clopidogrel); TAVI = transcatheter aortic valve implantation; TIA = transient ischaemic attack.
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with several on-going randomised trials (Figure 3). A detailed description 
of these investigations is beyond the scope of this article, but it is 
worthwhile commenting briefly on some of them due to their special 
interest (Table 2). 
The Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic 
Valve Implantation (POPular-TAVI; NCT02247128) trial will provide 
important insights into the management of antithrombotic treatment 
for TAVI patients. POPular-TAVI will assess the safety in terms of 
bleeding (primary endpoint) and the efficacy of the following regimens: 
aspirin monotherapy compared with DAPT with aspirin plus clopidogrel 
in a cohort of patients without an indication for OAC prior to TAVI 
(n=684); and OAC alone compared with OAC plus clopidogrel in a 
cohort of patients with an indication for OAC prior to TAVI (n=316). 
In patients without other indications for OAC, some small studies are 
evaluating the possible benefit of ticagrelor in this scenario, either in 
association with aspirin, in the Trial to Assess the Safety and Efficacy of 
Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel 
With Acetylsalicylic Acid in the Development of Cerebrovascular 
EMbolic Events During TAVI (PTOLEMAIOS; NCT02989558) trial, or in 
monotherapy in the Safety Profile Evaluation of TICagrelor Alone 
Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in 
the Context of Transcatheter Aortic Valve Implantation (TICTAVI; 
NCT02817789) study.
Several studies are trying to assess the usefulness of anticoagulation-
based strategies in TAVI patients without any other known indication 
for OAC. Of note, the Global Study Comparing a rivAroxaban-based 
Antithrombotic Strategy to an antipLatelet-based Strategy After 
Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes 
(GALILEO; NCT02556203) trial, which was evaluating the usefulness of 
a reduced dose of rivaroxaban (10 mg daily) in association with aspirin 
compared with standard DAPT, had to be prematurely terminated after 
enrolling 1,644 patients due to increased risks of all-cause mortality, 
thromboembolic events and bleeding in the rivaroxaban arm. The 
study has been recently published and its findings evidently cast 
doubts on the need for anticoagulant therapy in TAVI patients without 
any other indication for OAC (e.g. AF, mechanic valves, etc.).51
Other small-scale investigations will provide more information into the 
matter, such as the Dual Antiplatelet Therapy Versus Oral 
Anticoagulation for a Short Time to Prevent Cerebral Embolism After 
TAVI (AUREA; NCT01642134) and the Anticoagulant Versus Dual 
Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral 
Embolisation After Transcatheter Aortic Valve Replacement (ADAPT-
TAVR; NCT03284827) trials, which are comparing the effectiveness of 
VKA and edoxaban in monotherapy, respectively, versus standard 
DAPT with aspirin and clopidogrel. Of note, the results of the AUREA 
trial have been recently reported (but not published at the time this 
manuscript was written), showing that OAC with VKA failed to reduce 
the incidence of new subclinical ischaemic cerebral lesions, assessed 
by magnetic resonance imaging at 6 days and 3 months after TAVI, 
when compared with DAPT. 
Another small study, the Strategies to Prevent Transcatheter Heart 
Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement 
(LRT 2.0; NCT03557242), is evaluating the effect of adding VKA to aspirin 
compared with aspirin monotherapy.
Two relevant large trials are presently exploring the usefulness of 
DOACs following TAVI: the Anti-Thrombotic Strategy After Trans-Aortic 
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Treatment Arms Key Inclusion and Exclusion Criteria Primary Outcome
PTOLEMAIOS
(NCT02989558)
90 Aspirin + ticagrelor versus  
aspirin + clopidogrel
Inclusion: TAVI patients with high risk 
(EuroSCORE ≥18 or considered inoperable) 
for surgical valve replacement
Exclusion: Any condition requiring the 
use of anticoagulants 
Confirmed high intensity transient signals as  
assessed with transcranial Doppler between  
the two groups during the TAVI procedure
TICTAVI
(NCT02817789)
308 Ticagrelor versus aspirin + 
clopidogrel
Inclusion: Patient eligible for TAVI as 
recommended by French healthcare 
system authority
Exclusion: Need for chronic anticoagulation 
or previous PCI or ACS requiring DAPT
VARC2 composite endpoint (all-cause mortality, 
all stroke, life-threatening or disabling bleeding, 
acute kidney injury, coronary artery obstruction 
requiring intervention, major vascular complication, 
valve-related dysfunction requiring a new 
procedure) at 30 days
GALILEO
(NCT02556203)
1,644* Aspirin + rivaroxaban  
versus  
aspirin + clopidogrel
Inclusion: Successful TAVI of an aortic valve 
stenosis (either native of valve-in-valve)
Exclusion: Any indication for continued 
treatment with any OAC and any ongoing 
absolute indication for DAPT unrelated to 
the TAVI procedure
Efficacy: Composite of all-cause death and 
adjudicated any stroke, MI, symptomatic valve 
thrombosis, pulmonary embolism, deep vein 
thrombosis, or symptomatic valve thrombosis at 25 
months. 
Safety: Composite of life-threatening or disabling 
bleeding (BARC types 5 and 3b/3c) or major 
bleeding (BARC type 3a) at 25 months
AUREA
(NCT01642134)
123† VKA versus aspirin + 
clopidogrel
Inclusion: TAVI patients with symptomatic 
degenerative severe aortic stenosis 
rejected for conventional surgical aortic 
valve replacement due to unacceptable 
high risk 
Exclusion: Patients on chronic OAC treatment 
or those that cannot undergo DAPT or OAC for 
3 months due to any new post-TAVI indication




220 Edoxaban versus aspirin + 
clopidogrel
Inclusion: Successful TAVI on either native  
valve or valve-in-valve with any approved/
marketed device
Exclusion: Any indication for chronic OAC
Leaflet thrombosis on 4D, volume-rendered cardiac 
CT imaging at 6 months
LRT 2.0
(NCT03557242)
200 Aspirin + VKA  
versus aspirin
Inclusion: Low-risk (risk of death ≤3% by  
STS score) TAVI patients 
Exclusion: Other indications for OAC, 
bicuspid aortic valve or valve-in-valve 
procedures
Composite of all-cause mortality, all stroke, 
life-threatening and major bleeding, major vascular 
complications, hospitalisations for 
valve-related symptoms or worsening 
congestive heart failure, hypoattenuated leaflet 
thickening, at least moderately restricted  




1,000 No prior OAC indication:
Aspirin + clopidogrel  
versus aspirin
Prior OAC indication:
OAC + clopidogrel versus 
OAC
Inclusion: TAVI patients with and without 
other indication for long-term OAC.
Exclusion: DES implantation or BMS 
implantation within 3 and 1 months prior 
to TAVI procedure, respectively
All (BARC) bleeding complications at 1 year 
after TAVI. Co-primary endpoint: Non-procedure 
related bleeding complications at 1 year after TAVI
ATLANTIS
(NCT02664649)
1,510 No prior OAC indication: 
apixaban versus aspirin ± 
clopidogrel
Prior OAC indication: 
apixaban versus VKA
Inclusion: Patients undergoing a clinically 
successful TAVI procedure
Exclusion: Mechanical heart valve or 
necessary use of prasugrel or ticagrelor
Composite of death, MI, stroke, systemic embolism, 
intracardiac or bioprosthesis thrombus, any episode 
of deep vein thrombosis 
or pulmonary embolism, life-threatening or  
disabling or major bleeding at 1 year 
AVATAR
(NCT02735902)
170 OAC versus  
aspirin + OAC
Inclusion: Successful TAVI in patients 
requiring OAC
Exclusion: Coronary stenting for less than 
12 months and patients with high risk of  
bleeding
Composite of death from any cause, myocardial 
infarction, stroke all causes, valve thrombosis 





1,400 Edoxaban versus VKA Inclusion: Successful TAVI in patients 
requiring OAC due to AF
Exclusion: Comorbidities at high risk of  
bleeding
Composite of all-cause death, myocardial 
infarction), ischemic stroke, systemic embolic 
events, valve thrombosis, and ISTH major 
bleeding at 36 months. Co-primary endpoint: 
ISTH major bleeding at 36 months
*Prematurely terminated. †Completed (presented but not yet published). ACS = acute coronary syndrome; BARC = Bleeding Academic Research Consortium; BMS = bare metal stent; DAPT = 
dual antiplatelet therapy; ISTH = International Society on Thrombosis and Haemostasis; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; TAVI = transcatheter aortic valve 
implantation; VARC = Valve Academic Research Consortium; VKA = vitamin K antagonist.
Antithrombotic Therapy After TAVI
EUROPEAN CARDIOLOGY REVIEW
Valve Implantation for Aortic Stenosis (ATLANTIS; NCT02664649) study 
is evaluating the efficacy and safety of full-dose apixaban 5 mg twice 
daily (dose adjustment according to the drug label) compared either 
with VKA in patients with an indication other than TAVI for OAC or with 
standard of care antiplatelet therapy (DAPT or SAPT) in subjects 
without OAC indication; and the Edoxaban Compared to Standard 
Care After Heart Valve Replacement Using a Catheter in Patients with 
Atrial Fibrillation (ENVISAGE TAVI AF; NCT02943785) trial, which is 
comparing an edoxaban-based regimen with a VKA-based regimen in 
AF patients with indication for OAC after TAVI.
For patients with a concomitant indication for anticoagulation, the 
value, if any, of adding aspirin to OAC (VKA or DOAC) compared with 
OAC alone is being tested in the Anticoagulation Alone Versus 
Anticoagulation and Aspirin Following Transcatheter Aortic Valve 
Interventions (AVATAR; NCT02735902) trial. Finally, a significant 
proportion of AF patients undergoing TAVI is at increased risk of 
bleeding complications and, thus, may also have an absolute or 
relative contraindication for OAC. In this population, a non-
pharmacological approach with concomitant TAVI and left atrial 
appendage occlusion could be an attractive option. The efficacy and 
safety of this strategy is being evaluated in the WATCHMAN for 
Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve 
Replacement (WATCH-TAVR; NCT03173534) and the Comparison of 
Left Atrial Appendage Occlusion Versus Standard Medical Therapy in 
Patients in AF Undergoing TAVI (TAVI/LAAO; NCT03088098) trials.
Conclusion
The introduction of TAVI has represented an important breakthrough in 
cardiology and has changed the clinical practice for patients with aortic 
stenosis. Since the number of procedures is growing, it is crucial to 
determine the optimal antithrombotic therapy after TAVI, which to date 
remains a challenge due to the scarce available evidence. DAPT with 
aspirin and clopidogrel is the most commonly used strategy for patients 
without other indications for OAC, although recent evidence has 
questioned this approach, suggesting that SAPT with aspirin may be 
sufficient and less harmful in terms of bleeding in this setting. For 
patients with an indication for OAC other than TAVI (mostly AF), 
monotherapy with OAC appears to be the most suitable strategy. In the 
absence of contraindications, the use of DOACs in this scenario is 
appealing due to their better safety profile compared with VKA, but this 
hypothesis needs to be confirmed by dedicated studies. The results of 
several on-going trials will provide interesting insights on the subject in 
the upcoming years. 
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